Skip to main content

Peer Review reports

From: Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

Original Submission
27 Sep 2021 Submitted Original manuscript
17 Nov 2021 Reviewed Reviewer Report
21 Nov 2021 Reviewed Reviewer Report
14 Dec 2021 Author responded Author comments - Shelby Corman
Resubmission - Version 2
14 Dec 2021 Submitted Manuscript version 2
29 Dec 2021 Author responded Author comments - Shelby Corman
Resubmission - Version 3
29 Dec 2021 Submitted Manuscript version 3
17 Jan 2022 Author responded Author comments - Shelby Corman
Resubmission - Version 4
17 Jan 2022 Submitted Manuscript version 4
2 Feb 2022 Reviewed Reviewer Report
8 Feb 2022 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
11 Feb 2022 Editorially accepted
22 Mar 2022 Article published 10.1186/s12885-022-09364-z

You can find further information about peer review here.

Back to article page